The UK has signed agreements to provide 90 million doses of two possible COVID-19 vaccines from Pfizer Inc (PFE.N) and BioNTech (22UAy.F) and French Valneva Group (VLS.PA). This was announced by the United Kingdom authorities on Monday.
The UK has received 30 million doses of an experimental BioNTech/Pfizer vaccine and a 60 million-dose deal for Valneva, with an additional 40 million doses to choose from if proven safe, effective, and appropriate.
While no active vaccine against COVID-19 has been developed, there are currently three different types of vaccines to order in Britain, with a total of 230 million possible doses.
This new partnership with some of the world’s leading pharmaceutical and vaccine companies will give the United Kingdom the best chance of getting a vaccine that protects those most at risk.
Alok Sharma, UK Minister of Business
Financial terms of the transaction were not disclosed.
The new deals follow a previously announced agreement with AstraZeneca (AZN.L) that the firm will produce 100 million doses of its potential vaccine, which is being developed in collaboration with Oxford University.
Britain said it was the first such deal that Pfizer and BioNTech have agreed to supply their vaccine, which is being tested in its early and middle stages.
Firms seek to deliver up to 100 million doses by the end of this year, and possibly more than 1.2 billion doses by the end of 2021 if the vaccine is successful.
The BioNTech/Pfizer vaccine uses a so-called Messenger RNA (RNA messenger) approach, in contrast to the more traditional inactivated whole virus vaccine being developed by Valneva.
The potential Valneva vaccine is still in preclinical trials. The company intends to move to clinical trials by the end of 2020.
Britain also said it has provided treatment containing COVID-19 neutralizing antibodies from AstraZeneca (AZN.L) to protect people who cannot be vaccinated.